Ethris Announces Approval of Phase I Clinical Study for ETH47, a First-in-Class Inhaled mRNA for Respiratory Viral Infections

MUNICH, Germany, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Ethris GmbH, a leading biotechnology company pioneering next-generation RNA therapeutics and vaccines, today announced that it has received approval from the United

Related Keywords

Germany , United Kingdom , Munich , Bayern , German , Philipp Schreppel , Carsten Rudolph , Ethris Gmb , Lifesci Communications , Regulatory Agency , Clinical Trial Authorization , Stabilized Non Immunogenic , Stabilized Nanoparticle ,